Laboratory-confirmed Clostridioides difficile infection after potassium-competitive acid blocker versus proton pump inhibitor initiation in a new-user cohort

Abstract Background Comparative gastrointestinal infection safety of potassium-competitive acid blockers (PCABs) and proton pump inhibitors (PPIs) remains uncertain. In this study, we compared laboratory-confirmed Clostridioides difficile infection (CDI) after initiation of these drug classes in a hospital cohort. Methods In this retrospective active-comparator new-user cohort, prescription and stool-test records from a Korean hospital clinical data warehouse were linked. Adults initiated PCABs or PPIs between January 2020 and June 2025, after a 1-year washout for both drug classes and without CDI during the prior 5 years. PCAB and PPI initiators were matched 1:4 using propensity scores. Cox models estimated hazard ratios for incident laboratory-confirmed CDI. Results The matched cohort included 13,714 PCAB initiators and 54,856 PPI initiators, with 30 and 267 CDI events, respectively. Incidence rates were 5.69 and 7.15 per 1,000 person-years; mean observed follow-up was 140.5 and 248.8 days, respectively. PCAB initiation was associated with a lower observed CDI incidence (hazard ratio, 0.57; 95% confidence interval, 0.39–0.84). Nested secondary outcomes showed associations in the same direction. Conclusions In this single-center observational cohort, PCAB initiation was associated with a lower observed incidence of laboratory-confirmed CDI than PPI initiation. These findings add comparative gastrointestinal safety evidence for newer acid-suppressive therapies and support confirmation in multicenter cohorts. The observational association does not establish causal protection or individual-agent superiority.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-16
DOI
https://doi.org/10.21203/rs.3.rs-11564027/v1
Primary Topic
Clostridium difficile and Clostridium perfringens research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Laboratory-confirmed Clostridioides difficile infection after potassium-competitive acid blocker versus proton pump inhibitor initiation in a new-user cohort

Jun‐young Seo, Kwanjoo Lee, Ah Young Lee, Seung-Hun You et al.
2 links
Research Square
Clostridium difficile and Clostridium perfringens research
preprint

Laboratory-confirmed Clostridioides difficile infection after potassium-competitive acid blocker versus proton pump inhibitor initiation in a new-user cohort

Jun‐young Seo, Kwanjoo Lee, Ah Young Lee, Seung-Hun You, Wonsuk Shin
preprint en

Abstract

Abstract Background Comparative gastrointestinal infection safety of potassium-competitive acid blockers (PCABs) and proton pump inhibitors (PPIs) remains uncertain. In this study, we compared laboratory-confirmed Clostridioides difficile infection (CDI) after initiation of these drug classes in a hospital cohort. Methods In this retrospective active-comparator new-user cohort, prescription and stool-test records from a Korean hospital clinical data warehouse were linked. Adults initiated PCABs or PPIs between January 2020 and June 2025, after a 1-year washout for both drug classes and without CDI during the prior 5 years. PCAB and PPI initiators were matched 1:4 using propensity scores. Cox models estimated hazard ratios for incident laboratory-confirmed CDI. Results The matched cohort included 13,714 PCAB initiators and 54,856 PPI initiators, with 30 and 267 CDI events, respectively. Incidence rates were 5.69 and 7.15 per 1,000 person-years; mean observed follow-up was 140.5 and 248.8 days, respectively. PCAB initiation was associated with a lower observed CDI incidence (hazard ratio, 0.57; 95% confidence interval, 0.39–0.84). Nested secondary outcomes showed associations in the same direction. Conclusions In this single-center observational cohort, PCAB initiation was associated with a lower observed incidence of laboratory-confirmed CDI than PPI initiation. These findings add comparative gastrointestinal safety evidence for newer acid-suppressive therapies and support confirmation in multicenter cohorts. The observational association does not establish causal protection or individual-agent superiority.

Research Square
CHA University Bundang Medical Center (KR), CHA University (KR), CHA University Gangnam Medical Center (KR)
Good health and well-being
Clostridium difficile and Clostridium perfringens research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon